Mednet Logo

What would you offer as adjuvant therapy for a resected stage IIIB adeno NSCLC in a patient who refuses chemotherapy?

Can adjuvant durvalumab or other I/O or osimertinib (if EGFR+) be considered?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · The Ohio State University School of Medicine
Answered on

Patients with stage III NSCLC are at very high risk for recurrence, and in this situation, I would make sure that your discussions with the patient highlight this clearly. My usual thought is that if a patient can tolerate and recover from lobectomy/resection, then that is a reasonable indication th...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Yuma Regional Medical Center Cancer Center
Answered on

I would definitely have an honest conversation with the patient about high risk of relapse. Sometimes it's just addressing the barriers and fears associated with chemotherapy. Like Dr. @Dr. First Last mentioned, using carboplatin does significantly decrease the platinum related AE's. Sometimes I ten...

Join for free or sign in to see the full answer